Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Extendicare's gross profit for the
three
months ended in Mar. 2026 was $339 Mil. Extendicare's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was $1,273 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Extendicare's gross profit for the
three
months ended in Mar. 2026 was $339 Mil. Extendicare's Revenue for the
three
months ended in Mar. 2026 was $339 Mil. Therefore, Extendicare's Gross Margin % for the quarter that ended in Mar. 2026 was N/A%.
Extendicare had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Extendicare had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Extendicare Gross Profit Related Terms
Extendicare Gross Profit Historical Data
* Premium members only.
The historical data trend for Extendicare's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Extendicare's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Extendicare Gross Profit vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Extendicare's Gross Profit distribution charts can be found below:
* The bar in red indicates where Extendicare's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,273 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
(Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Extendicare (EXETF) has a Gross Profit of $1,273 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Extendicare and its competitors.
Is Extendicare's Gross Profit too high?
Extendicare's current Gross Profit is $1,273 Mil. Overall, Extendicare has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Extendicare's Gross Profit compare to HCA and THC?
Extendicare's Gross Profit of $1,273 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Healthcare Providers & Services company?
A good Gross Profit depends on the Healthcare Providers & Services industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Extendicare and its competitors. Extendicare's current Gross Profit is $1,273 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extendicare stock overvalued right now?
Based on GuruFocus' analysis, Extendicare (EXETF) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.12, compared to a current price of $26.97 — trading 166.5% above its estimated fair value. The current Gross Profit is $1,273 Mil. Extendicare's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Extendicare (EXETF), the current Gross Profit is $1,273 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Extendicare (EXETF) Overvalued in 2026?
Based on GuruFocus' analysis, Extendicare stock appears to be overvalued.
The current stock price of $26.97 is trading 166.5% above its estimated GF Value™ of $10.12.
GuruFocus considers Extendicare to be Significantly Overvalued.
Key valuation signals for EXETF:
Gross Profit: $1,273 Mil
GF Value™: $10.12 vs. price of $26.97 (166.5% above fair value)
No single metric tells the full story. See the EXETF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Extendicare Inc is a senior care provider in Canada, focused on long-term care and home health care. The has three main business segments: Long-term Care (LTC), Home Health Care, and Managed Services. The Long-term Care segment, operating under the Extendicare brand, represents 53 owned homes in Ontario, Alberta and Manitoba. The Home Health Care segment, operating under the ParaMed brand, provides home health care services annually in Ontario, Alberta, Manitoba and Nova Scotia. The Managed Services segment, operating under the Extendicare Assist and SGP Purchasing Partner Network brands, provides management, consulting and group purchasing services to other care providers across Canada. The majority of the company's revenue is derived from the Long-term Care segment.
71GF Score
Get the complete analysis for EXETF
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EXETF has been successfully added to your 
